Lasilactone 50 Tablet is a combination diuretic formulation containing Furosemide 20 mg and Spironolactone 50 mg, designed to manage fluid retention and edema associated with various medical conditions. Furosemide, a potent loop diuretic, acts on the ascending limb of the loop of Henle to inhibit sodium and chloride reabsorption, promoting increased urine output and reducing excess fluid accumulation. Spironolactone, a potassium-sparing diuretic and aldosterone antagonist, works at the distal renal tubules to inhibit sodium reabsorption while conserving potassium, thereby minimizing hypokalemia risk commonly associated with loop diuretics. This synergistic combination is particularly effective in treating congestive heart failure, hepatic cirrhosis with ascites, nephrotic syndrome, and hypertension where fluid overload is a concern. Lasilactone 50 Tablet should be administered under medical supervision with regular monitoring of electrolyte levels, renal function, and blood pressure to avoid potential adverse effects such as hyperkalemia, dehydration, or renal impairment. Patients with hypersensitivity to either component, severe renal insufficiency, or hyperkalemia should avoid this medication. The combined diuretic effect facilitates optimal fluid balance management, improving clinical outcomes in patients with edematous states and related cardiovascular or renal disorders.